Phaseline

Companies › Regor Pharmaceuticals

Regor Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RGT-419B
unclear - likely a kinase inhibitor based on context of CDK4/6i resistant breast cancer
–Phase 1Breast CancerDec 2026
RGT-490
PIK3CA inhibitor
PIK3CAPhase 1Breast CancerApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05304962RGT-419BPhase 1Breast CancerOncologyDec 2026
NCT06299124RGT-419BPhase 1Breast CancerOncologyDec 2026
NCT07524322RGT-490Phase 1Breast CancerOncologyApr 2028

Targets

PIK3CA (1)

Companies with the same targets

Eli Lilly Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Totus Medicines Risen (Suzhou) Pharma Tech iOnctura Restorbio Roche Haihe Biopharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.